|
Avanti
Therapeutic’s innovations feed the company's in-house product development and
commercialization, and power programs currently under development by numerous
partners. At the heart of Avanti's product development are four product
platforms:
|
Product Candidate |
Primary Indication |
Partner Licensee |
Status |
|
Hepatitis B DNA Vaccine |
Hepatitis B |
Internal Development |
Mid
preclinical |
|
ATGC-OP0359 |
Prostate Cancer |
Internal Development |
Discovery |
|
Staphylocide |
Drug
resistant Infections |
BPI
Technology |
Late
preclinical |
|
Malaria DNA Vaccine |
Malaria |
Internal Development |
Mid preclinical |
|
Tuberculosis Vaccine |
MDR
Tuberculosis |
Internal Development |
Early
preclinical |
|
Hepatitis B Recombinant Vaccine |
Hepatitis B |
AT-GC
BioPharm |
Mid
preclinical |
|
Discovery research |
Dengue Fever |
Photochem Laboratoties |
Discovery |
|
HPy-HP 097 |
Peptic ulcer |
Internal Development |
Mid
preclinical |
| |
|
|
|
|
|
